The evolving landscape of drug therapy demands a rethinking of established approaches. Present research is altering focus towards individualized treatment regimens, combining genomics, proteomics, and other advanced biomarkers to foresee patient response and lessen adverse reactions. This developing paradigm emphasizes precise interventions, aiming